恩华药业获机构关注，行业政策利好频出

Group 1 - The pharmaceutical and biotechnology industry is experiencing favorable policy developments, such as the National Healthcare Security Administration's release of the "Drug Communication Method (Trial)" and the joint issuance of the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" by eight departments, which supports innovative pharmaceutical companies [1] - Enhua Pharmaceutical (002262), as a chemical pharmaceutical company, has a target price set at 32.00 yuan by institutions, with the latest price at 23.87 yuan, and a projected net profit growth of 21.63% year-on-year by 2026, indicating positive growth expectations [1] - Current institutional ratings for Enhua Pharmaceutical are neutral, but there is attention on the trend of profit improvement [1] Group 2 - Over the past week (February 6, 2026 - February 12, 2026), Enhua Pharmaceutical's stock price fluctuated within a range of 1.83%, with a maximum price of 24.10 yuan on February 12 and a minimum price of 23.20 yuan on February 6 [1] - On February 12, there was a net inflow of 4.8174 million yuan from major investors, and technical indicators show a fluctuating pattern, with a resistance level at 24.82 yuan and a support level at 22.76 yuan [1] - The pharmaceutical sector's return was 3.28%, outperforming the CSI 300 index, indicating a recovery in industry sentiment [1] Group 3 - On February 11, the financing purchase amount was 2.6204 million yuan, with a financing balance of 582 million yuan, reflecting active market liquidity [1] - There have been no significant announcements from the company recently, but industry policy dynamics may indirectly affect its valuation [1]